As shown, GLP-1R agonists target three mechanisms involving reduced inflammation, reduced insulin resistance, and the control of glucose homeostasis, which could collectively result in the downregulation of non-collagen proteins (Figure 5). This evidence concerns the gene GLP1R and Insulin resistance.